Press Releases AlzeCure Pharma AB

Equities

ALZCUR

SE0010133785

Delayed Nasdaq Stockholm Other stock markets 08:11:41 15/05/2024 BST			5-day change	1st Jan Change
1.77 ^SEK	-0.56%		-0.28%	-42.77%

05-14	AlzeCure Pharma AB Approves the Election of Jan Lundberg as New Ordinary Members of the Board of Directors	CI
04-25	AlzeCure Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Communiqué from the annual general meeting of AlzeCure Pharma on 14 May 2024	05-14	AQ
AlzeCure reports anti-inflammatory effects with NeuroRestore ACD856 with relevance to Alzheimer's leading to new patent application	05-13	AQ
AlzeCure Pharma publishes prospectus	04-29	AQ
AlzeCure publishes its interim report for January – March 2024	04-25	AQ
Eli Lilly's and AstraZeneca's former head of research Dr. Jan Lundberg invests in AlzeCure and is proposed for election to its board	04-10	AQ
AlzeCure Pharma publishes its Annual Report for 2023	04-04	AQ
AlzeCure presents new data regarding the TrkA-NAM pain project at IASP 2024	04-03	AQ
AlzeCure to partake in Redeye Theme, Alzheimer on March 21	03-15	AQ
AlzeCure to partake in Redeye Theme: Alzheimer on March 21	03-14	AQ
AlzeCure presents new preclinical data with NeuroRestore ACD856 at leading Alzheimer's conference	03-07	AQ
AlzeCure publishes clinical results supporting continued development of NeuroRestore ACD856 against Alzheimer's	03-05	AQ
AlzeCure's Alzheimer's project NeuroRestore ACD856 is granted an additional patent	02-29	AQ
AlzeCure publishes its Year-end report for January – December 2023	02-27	AQ
AlzeCure Pharma broadcasts live expert event on Alzheimer's around highly current gamma-secretase modulators	02-12	AQ
AlzeCure gets Late Breaking abstract of new preclinical data with ACD856 accepted at AD/PD 2024 conference	02-06	AQ
AlzeCure CEO Martin Jonsson to present at the international investor conference BioCapitalEurope	02-01	AQ
AlzeCure CEO Martin Jönsson to present at the international investor conference BioCapitalEurope	01-31	AQ
AlzeCure selects drug candidate and enters next phase of development with TrkA-NAM ACD137 against severe pain	01-29	AQ
AlzeCure Pharma	01-26	AQ
The government draws attention to Swedish Alzheimer's research and together with the Swedish Alzheimer's Foundation visit AlzeCure Pharma	01-18	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases AlzeCure Pharma AB

Equities

ALZCUR

SE0010133785

Press Releases

Filters